Aduro Biotech Company Profile (NASDAQ:ADRO)

Aduro Biotech trades on the NASDAQ under the ticker symbol "ADRO."

Aduro Biotech, Inc. (NASDAQ:ADRO) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.02. The company earned $5.90 million during the quarter, compared to the consensus estimate of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The company's revenue for the quarter was down 84.9% compared to the same quarter last year. During the same period last year, the firm posted $0.03 EPS. View Aduro Biotech's Earnings History.

8 brokers have issued 12-month target prices for Aduro Biotech's shares. Their predictions range from $14.00 to $30.00. On average, they anticipate Aduro Biotech's share price to reach $20.00 in the next twelve months. View Analyst Ratings for Aduro Biotech.

Here are some recent quotes from research analysts about Aduro Biotech stock:

• 1. According to Zacks Investment Research, "Aduro’s lead candidate, CRS-207, being evaluated for a number of cancer indications, bodes well for long-term growth. Moreover, its collaboration agreements with large pharma companies, Novartis, Johnson & Johnson and Incyte are big positives for the company. Aduro has a broad and a promising pipeline of novel immunotherapies under development for the treatment of a variety of cancers. Aduro’s efforts to develop its pipeline are encouraging. However, Aduro depends largely on funds generated from collaboration and license agreements, government grants and other payments for the development of its pipeline candidates. Thus, inability to secure sufficient funding could hinder its pipeline progress. Aduro’s shares underperformed the industry in the last one year. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters." (8/2/2017)
• 2. Canaccord Genuity analysts commented, "1Q17 results recap. Adjusted non-GAAP revenue (excluding the individual commercial business) grew 4.4% year over year. Adjusted MLR was 85.2% compared to 85.0% a year ago. MLR benefitted from the exit of certain Medicare markets, which was offset to some degree by lower prior period development when compared to a year ago. Cost trends appear to be in check, consistent with other publicly-traded health insurers." (5/3/2017)
• 3. FBR & Co analysts commented, "Aduro Biotech, Inc.’s (ADRO) cancer immunotherapy platform triggers both innate and adaptive immunity, resulting in a broad and potent multi-pronged immune response. The company’s engineered live, attenuated, double-deleted (LADD) Listeria monocytogenes program is capable of inducing an antigen-specific adaptive T-cell response (CD8+ and CD4+), as well as an innate immune response that includes cytokines, chemokines, gamma delta T cells, and NK cells. The company’s STING (Stimulator of Interferon Genes, driven by cytosolic DNA) platform induces dendritic cells and enhances an anti-tumor T-cell response in the tumor microenvironment. Aduro’s third technology platform is B-select, based on clonal expansion of B cells producing highly selective and functional antibodies against targets that regulate the immune response. Given that the future of cancer immunotherapy points to combinations, Aduro’s programs are complementary combination approaches that activate distinct mechanisms of actions that could be synergistic." (3/7/2017)

Some companies that are related to Aduro Biotech include AnaptysBio (ANAB), Clinigen Group PLC (CLIN), Five Prime Therapeutics (FPRX), Acorda Therapeutics (ACOR), Dermira (DERM), Lexicon Pharmaceuticals (LXRX), MyoKardia (MYOK), Sangamo Therapeutics (SGMO), Ascendis Pharma A/S (ASND), Dynavax Technologies Corporation (DVAX), NeuroDerm (NDRM), Xencor (XNCR), REGENXBIO (RGNX), Epizyme (EPZM), Athenex (ATNX), Ignyta (RXDX), Retrophin (RTRX) and Amarin Corporation PLC (AMRN).

Aduro Biotech's management team includes the folowing people:

• Stephen T. Isaacs, Chairman of the Board, President and Chief Executive Officer
• Gregory W. Schafer, Chief Operating Officer
• Blaine Templeman, Executive Vice President, General Counsel, Secretary
• Dirk G. Brockstedt, Executive Vice President of Research and Development
• Jennifer Lew CPA, Senior Vice President - Finance
• Andrea van Elsas Ph.D., Chief Scientific Officer
• Natalie R. Sacks, Chief Medical Officer
• Stephanie Monaghan O'Brien J.D., Lead Independent Director
• Gerald Chan Ph.D., Independent Director
• William M. Greenman, Independent Director

(ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aduro Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include MORNINGSIDE VENTURE (VI) INVESTMENTS LTD (12.47%). Company insiders that own Aduro Biotech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro Biotech.

Shares of Aduro Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Aduro Biotech stock can currently be purchased for approximately $9.23.